Trial · NCT03829319
Participant flow15
How many started, completed or left each group, period by period.
1 to 15 of 15
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 13 | |
| Overall Study | STARTED | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 375 | |
| Overall Study | STARTED | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 373 | |
| Overall Study | Treated During First Course | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 13 | |
| Overall Study | Treated During First Course | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 373 | |
| Overall Study | Treated During First Course | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 372 | |
| Overall Study | Treated During Second Course | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | |
| Overall Study | Treated During Second Course | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 3 | |
| Overall Study | Treated During Second Course | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 5 | |
| Overall Study | COMPLETED | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 0 | |
| Overall Study | COMPLETED | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 0 | |
| Overall Study | COMPLETED | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 0 | |
| Overall Study | NOT COMPLETED | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 13 | |
| Overall Study | NOT COMPLETED | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 375 | |
| Overall Study | NOT COMPLETED | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 373 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03829319/flow